AMARIN CORP PLCUK
AMRN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AMRN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AMRN
Amarin Corporation PLC is a biopharmaceutical company focused on the commercialization of its lead product VASCEPA (icosapent ethyl) for cardiovascular risk reduction, with a recent strategic shift toward expanding in international markets and managing its U.S. patent estate.
Key risk: Single product dependency
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 catalyst for AMARIN CORP PLCUK.
Amarin Corporation PLC is a biopharmaceutical company focused on the commercialization of its lead product VASCEPA (icosapent ethyl) for cardiovascular risk reduction, with a recent strategic shift toward expanding in international markets and managing its U.S. patent estate.
- Lead product VASCEPA (icosapent ethyl) is approved for cardiovascular risk reduction; the company is pursuing regulatory filings in Rest of World markets [sec · filed 2026-04-10].
- As of June 30, 2026, Amarin had cash and cash equivalents of $143.6 million and short-term investments of $171.1 million, aggregating $314.6 million [sec_mda · as of 2026-07-29].
- For the six months ended June 30, 2026, total revenue was $42.2 million and net loss was $7.7 million [latest reported financials (as of 2026-06-30)].
- The company has an authorized $50.0 million share repurchase program (approved through Q2 2029) but has not yet commenced any repurchases [sec_mda · as of 2026-03-02].
- Amarin reduced operating costs by $50.0 million annually through restructuring its European commercial operations [sec_mda · as of 2025-03-12].
What works
- Amarin maintains a strong liquidity position with $314.6 million in cash, cash equivalents, and short-term investments as of June 30, 2026, and no debt [sec_mda · as of 2026-07-29].
- The company has achieved meaningful regulatory progress in Rest of World markets, including accelerated CVRR filings, which could diversify revenue beyond the U.S. [sec · filed 2026-04-10].
- Amarin has a disciplined cost structure, having reduced annual operating costs by $50.0 million through restructuring European operations [sec_mda · as of 2025-03-12].
What to weigh
- Amarin is heavily dependent on a single product, VASCEPA, whose U.S. patent exclusivity expires on June 28, 2033, exposing it to generic competition [upcoming catalysts (authoritative, structured, real dates)].
- The company has incurred annual operating losses since inception and reported a net loss of $7.7 million for the six months ended June 30, 2026 [sec_mda · as of 2025-05-07; latest reported financials (as of 2026-06-30)].
- The $50.0 million share repurchase program has not been initiated, indicating management may be conserving cash amid uncertainty [sec_mda · as of 2026-03-02].
- Revenue concentration in the U.S. market remains a risk, as international expansion is still in early stages and subject to pricing and reimbursement hurdles [sec_mda · as of 2025-03-12].
From the filings
Quoted directly from source documents.
Amarin's cash and short-term investments position as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $143.6 million and short-term investments of $171.1 million, aggregating $314.6 million.”
SEC MD&A · July 29, 2026
Amarin's $50 million share repurchase program has not been initiated
“The Company has not commenced any share repurchases to date, but we will continue to monitor business and market conditions.”
SEC MD&A · March 2, 2026
Catalyst timeline
- 2033-06-28 · Patent_Expiry · VASCEPA — Patent/Exclusivity Expiry: VASCEPA — The expiration of VASCEPA's U.S. patent exclusivity could allow generic competition, significantly impacting revenue.
Risks & what to watch (4)›
Key risks
- Single product dependency — Amarin's revenue is almost entirely from VASCEPA; loss of exclusivity or market share would severely impact financials [sec_mda · as of 2026-07-29].
- Patent expiry in 2033 — U.S. patent exclusivity for VASCEPA expires June 28, 2033, opening the door to generic competition [upcoming catalysts].
- History of operating losses — Amarin has incurred annual operating losses since inception and reported a net loss of $7.7M in H1 2026 [sec_mda · as of 2025-05-07; latest financials].
- International expansion uncertainty — Regulatory and commercial success in Rest of World markets is unproven and faces pricing/reimbursement hurdles [sec_mda · as of 2025-03-12].
What to watch
- Progress of VASCEPA regulatory filings and approvals in Rest of World markets, particularly CVRR submissions [sec · filed 2026-04-10].
- Any initiation of the $50.0 million share repurchase program, which remains authorized through Q2 2029 [sec_mda · as of 2026-03-02].
- U.S. revenue trends for VASCEPA, especially as the patent expiry date approaches in 2033 [upcoming catalysts].
- Updates on cost structure and operating expense management following the European restructuring [sec_mda · as of 2025-03-12].
Sources: SEC filings · SEC MD&A · Generated August 15, 2026 · How we verify sources →
Run AMARIN CORP PLCUK through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AMARIN CORP PLCUK facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.41 · 0% dilution
Lead: Approved
3 candidates
1 upcoming, next in ~2494d
No insider transactions in the last 180 days
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
63
Total value held
$45.7M
| Holder | Shares | Value |
|---|---|---|
| sarissa capital management lp | 1,673,395 | $24.2M |
| millennium management llc | 300,536 | $4.3M |
| morgan stanley | 293,172 | $4.2M |
| waterfront wealth inc. | 203,338 | $2.9M |
| two sigma investments, lp | 107,542 | $1.6M |
| susquehanna international group, llp | 95,767 | $1.4M |
| citadel advisors llc | 91,575 | $1.3M |
| bnp paribas financial markets | 75,503 | $1.1M |
| lcm capital management inc | 43,462 | $628K |
| state street corp | 24,949 | $361K |
Showing top 10 of 63 institutional holders of AMARIN CORP PLCUK. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.3%
- Days to cover
- 10.3
- Shares short
- 673,967
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMRN short interestGovernance
Frequently asked questions
What is the AI investment thesis for AMARIN CORP PLCUK?
Amarin Corporation PLC is a biopharmaceutical company focused on the commercialization of its lead product VASCEPA (icosapent ethyl) for cardiovascular risk reduction, with a recent strategic shift toward expanding in international markets and managing its U.S. patent estate.
What is AMARIN CORP PLCUK's lead drug candidate?
AMARIN CORP PLCUK's most advanced tracked candidate is vascepa (Approved) for Reducing triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia; reducing persistent cardiovascular risk in select high-risk patients as an adjunct to maximally tolerated statin therapy..
What is AMARIN CORP PLCUK's next catalyst?
AMARIN CORP PLCUK's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VASCEPA" — expected June 28, 2033.
Who is the CEO of AMARIN CORP PLCUK?
Mr. Aaron D. Berg is the chief executive officer of AMARIN CORP PLCUK (AMRN).
Where is AMARIN CORP PLCUK headquartered?
AMARIN CORP PLCUK (AMRN) is headquartered in Dublin, Ireland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.